Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World

瑞戈非尼 医学 内科学 结直肠癌 不利影响 队列 队列研究 观察研究 肿瘤科 外科 癌症
作者
Qi Zhang,Mifen Chen,Zhenghang Wang,Changsong Qi,Yanshuo Cao,Junyan Zhang,Zhi Peng,Xicheng Wang,Ming Lu,Lin Shen,Jian Li
出处
期刊:Clinical Colorectal Cancer [Elsevier BV]
卷期号:21 (3): e152-e161 被引量:8
标识
DOI:10.1016/j.clcc.2022.01.007
摘要

BackgroundRegorafenib and fruquintinib are tyrosine kinase inhibitors that are recommended for refractory colorectal cancer (CRC) in China. However, to date, no head-to-head trials have been conducted to guide clinical practice.Methods and PatientsAn ambispective observational cohort study was conducted in Beijing Cancer Hospital. Patients with metastatic CRC who received regorafenib or fruquintinib were retrospectively collected between January 2018 and April 2020, and prospectively enrolled between May 2020 and February 2021. The primary outcome was time-to-treatment failure (TTF), and secondary outcomes were overall survival (OS) and adverse events. An additional goal of the study was to explore the appropriate sequence of regorafenib and fruquintinib treatment.ResultsA total of 366 patients with metastatic CRC were enrolled to receive regorafenib (n = 260) or fruquintinib (n = 106) between January 2018 and February 2021. No difference was observed for median TTF (regorafenib 2.7 months vs. fruquintinib 3.1 months, P = .200) or median OS (regorafenib 13.8 months vs. fruquintinib 11.3 months, P = .527). The propensity score analysis showed similar results for median TTF and median OS between the 2 groups, as did the results of subgroup analysis for prospective set (n = 146). For sequence analysis, patients with regorafenib followed by fruquintinib (n = 84) showed longer OS than that with the reverse (n = 29) (28.1 months vs. 18.4 months, P = .024). Most patients tolerated regorafenib at a reduced dose (93.1%), and most patients tolerated fruquintinib at a standard dose (68.9%). The incidences of most adverse events were similar between the two groups, while any grade of hand-foot skin reaction and hyperbilirubinemia were more frequently observed in the regorafenib group and ≥grade 3 hypertension was more common in the fruquintinib group.ConclusionRegorafenib and fruquintinib had similar efficacy and toxicity profiles with various frequency. Regorafenib followed by fruquintinib showed longer OS than the reverse, but the sequence needs to be further confirmed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
liuyuh完成签到,获得积分10
刚刚
悠明夜月完成签到 ,获得积分10
1秒前
乌云乌云快走开完成签到,获得积分10
1秒前
你是我的唯一完成签到 ,获得积分10
1秒前
洁白的故人完成签到 ,获得积分10
3秒前
乐观半兰发布了新的文献求助10
3秒前
water应助科研通管家采纳,获得10
4秒前
zhang完成签到 ,获得积分10
4秒前
water应助科研通管家采纳,获得10
4秒前
Jasper应助科研通管家采纳,获得10
4秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
orixero应助科研通管家采纳,获得10
4秒前
CodeCraft应助科研通管家采纳,获得10
4秒前
大模型应助科研通管家采纳,获得10
4秒前
4秒前
鲲鹏完成签到 ,获得积分10
5秒前
大气建辉完成签到 ,获得积分10
5秒前
尛森完成签到,获得积分10
5秒前
机灵枕头完成签到 ,获得积分10
6秒前
糖糖科研顺利呀完成签到 ,获得积分10
8秒前
辣小扬完成签到 ,获得积分10
10秒前
传奇3应助水晶茶杯采纳,获得10
12秒前
幽默的素阴完成签到 ,获得积分10
16秒前
小小鱼完成签到 ,获得积分10
23秒前
23秒前
甜美砖家完成签到 ,获得积分10
25秒前
superspace完成签到,获得积分10
26秒前
nn发布了新的文献求助10
28秒前
求助完成签到,获得积分10
29秒前
30秒前
翁雁丝完成签到 ,获得积分10
37秒前
郭义敏完成签到,获得积分0
37秒前
gyf完成签到,获得积分10
40秒前
李保龙完成签到 ,获得积分10
41秒前
45秒前
LJJ完成签到 ,获得积分10
46秒前
量子星尘发布了新的文献求助10
49秒前
阿姨洗铁路完成签到 ,获得积分10
54秒前
抹不掉的记忆完成签到,获得积分10
56秒前
56秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022